International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 05 Issue 04 April 2025

Page No: 516-521

DOI: https://doi.org/10.47191/ijmscrs/v5-i04-03, Impact Factor: 8.188

Contemporary Management of Adrenal Insufficiency: A Comprehensive Review of Diagnostic Strategies, Therapeutic Interventions, and Long-Term Monitoring

Elsa Itzel calderón Tapia[1], Carlos Emmanuel Guzman Solorzano[1], Jesus Miguel Valencia Correa[1], Araceli Martínez Cervantes[1], Meyboll Edily Rodriguez Medina[1]

[1]Hospital Regional Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Leon Guanajuato, México. Servicio de medicina interna.

ABSTRACT

Adrenal insufficiency (AI) is a life-threatening endocrine disorder characterized by inadequate production or action of glucocorticoids, with or without deficiency in mineralocorticoids and adrenal androgens. The condition can be primary (due to adrenal gland dysfunction), secondary (due to pituitary dysfunction), or tertiary (due to hypothalamic dysfunction). The management of AI has evolved significantly over the past decade, with advancements in diagnostic modalities, glucocorticoid replacement therapies, and patient education. This article provides a comprehensive review of the current diagnostic approaches, including dynamic endocrine testing and imaging studies, as well as the latest therapeutic strategies, such as individualized glucocorticoid dosing, dual-release formulations, and the emerging role of circadian rhythm-based therapies. Additionally, the importance of patient education, self-management, and long-term monitoring to prevent adrenal crises and optimize quality of life is emphasized. The review also highlights the challenges in managing special populations, including pediatric patients, pregnant women, and those with concurrent comorbidities. By integrating the latest evidence-based practices, this article aims to guide clinicians in delivering optimal care for patients with adrenal insufficiency.

KEYWORDS: Adrenal insufficiency, glucocorticoid replacement, adrenal crisis, hypothalamic-pituitary-adrenal axis, cortisol deficiency, mineralocorticoid deficiency, dynamic endocrine testing, circadian rhythm-based therapy, patient education, long-term monitoring.

ARTICLE DETAILS

Published On:
05 April 2025

Available on:
https://ijmscr.com

INTRODUCTION

Adrenal insufficiency (AI) is a complex endocrine disorder that arises from the inadequate secretion of cortisol, often accompanied by deficiencies in aldosterone and adrenal androgens. The condition is classified into primary adrenal insufficiency (PAI), secondary adrenal insufficiency (SAI), and tertiary adrenal insufficiency (TAI), each with distinct etiologies and pathophysiological mechanisms. PAI, also known as Addison's disease, is primarily caused by autoimmune destruction of the adrenal cortex, whereas SAI and TAI result from impaired secretion of adrenocorticotropic hormone (ACTH) by the pituitary gland or corticotropin-releasing hormone (CRH) by the hypothalamus, respectively. The clinical presentation of AI is often insidious, with nonspecific symptoms such as fatigue, weight loss, hypotension, and hyponatremia, which can lead to delayed diagnosis and increased morbidity.1,2

The management of AI has undergone significant advancements in recent years, driven by a deeper understanding of the hypothalamic-pituitary-adrenal (HPA) axis and the development of innovative therapeutic approaches. Traditional glucocorticoid replacement therapies, such as hydrocortisone and prednisone, have been the cornerstone of treatment; however, these regimens often fail to replicate the physiological cortisol circadian rhythm, leading to suboptimal outcomes and an increased risk of long-

term complications. Recent innovations, including dual-release hydrocortisone formulations and continuous subcutaneous cortisol infusion pumps, aim to mimic the natural cortisol secretion pattern more closely, thereby improving metabolic control and reducing adverse effects.1,2 Despite these advancements, the management of AI remains challenging, particularly in special populations such as pediatric patients, pregnant women, and individuals with comorbid conditions. Moreover, the risk of life-threatening adrenal crises, often triggered by infections, surgery, or stress, underscores the importance of patient education and self-management strategies. This article seeks to provide a comprehensive overview of the current diagnostic and therapeutic approaches to AI, with a focus on optimizing patient outcomes through individualized treatment plans, advanced monitoring techniques, and multidisciplinary care. By synthesizing the latest evidence and clinical guidelines, this review aims to equip healthcare providers with the knowledge and tools necessary to address the complexities of adrenal insufficiency in the modern era.2,3

BACKGROUND

Adrenal insufficiency (AI) is a multifaceted endocrine disorder characterized by the impaired synthesis and secretion of adrenal hormones, primarily cortisol, and in some cases, aldosterone and adrenal androgens. The condition is classified into primary adrenal insufficiency (PAI), secondary adrenal insufficiency (SAI), and tertiary adrenal insufficiency (TAI), each with distinct etiological and pathophysiological underpinnings. PAI, historically known as Addison's disease, was first described by Thomas Addison in 1855 and is most commonly caused by autoimmune adrenalitis, which accounts for approximately 80-90% of cases in developed countries. Other causes of PAI include infections (e.g., tuberculosis, HIV-associated opportunistic infections), adrenal hemorrhage, genetic disorders (e.g., congenital adrenal hyperplasia, adrenoleukodystrophy), and metastatic disease. SAI and TAI, on the other hand, result from dysfunction at the level of the pituitary gland and hypothalamus, respectively, leading to insufficient stimulation of the adrenal cortex and subsequent cortisol deficiency. Common causes of SAI include pituitary tumors, surgery, radiation therapy, and traumatic brain injury, while TAI is often associated with chronic glucocorticoid therapy and subsequent suppression of the hypothalamic-pituitary-adrenal (HPA) axis.3,4

The clinical presentation of AI is often insidious and nonspecific, making early diagnosis challenging. Patients may present with symptoms such as chronic fatigue, weight loss, anorexia, orthostatic hypotension, hyponatremia, and hyperkalemia (in cases of mineralocorticoid deficiency). The hallmark of AI is the inability to mount an adequate stress response, which can precipitate an adrenal crisis—a life-threatening condition characterized by hypotension, hypoglycemia, and shock. The diagnosis of AI relies on a combination of clinical suspicion, biochemical testing, and imaging studies. Dynamic endocrine tests, such as the ACTH stimulation test, insulin tolerance test, and CRH stimulation test, are commonly employed to assess the integrity of the HPA axis. Additionally, imaging modalities, including computed tomography (CT) of the adrenal glands and magnetic resonance imaging (MRI) of the pituitary gland, are utilized to identify structural abnormalities and guide etiological diagnosis.4

The management of AI has evolved significantly over the past century, from the isolation and synthesis of cortisone in the 1940s to the development of advanced glucocorticoid replacement therapies in the modern era. Traditional treatment regimens, such as hydrocortisone and prednisone, have been the mainstay of therapy; however, these approaches often fail to replicate the physiological circadian rhythm of cortisol secretion, leading to suboptimal metabolic control and an increased risk of long-term complications, including osteoporosis, cardiovascular disease, and impaired quality of life. Recent advancements in pharmacotherapy, such as dual-release hydrocortisone formulations and continuous subcutaneous cortisol infusion pumps, aim to more closely mimic the natural cortisol secretion pattern, thereby improving patient outcomes. Additionally, the role of patient education and self-management cannot be overstated, as adherence to glucocorticoid replacement therapy and the ability to adjust doses during periods of stress are critical in preventing adrenal crises.4,5

Despite these advancements, the management of AI remains fraught with challenges, particularly in special populations such as pediatric patients, pregnant women, and individuals with comorbid conditions. Pediatric patients with AI require careful dose adjustments to accommodate growth and development, while pregnant women necessitate close monitoring to ensure optimal maternal and fetal outcomes. Furthermore, the management of AI in the context of concurrent illnesses, such as diabetes mellitus and autoimmune diseases, requires a multidisciplinary approach to address the complex interplay of hormonal and metabolic factors.4,5

In conclusion, the management of adrenal insufficiency has undergone significant progress, yet it remains a complex and challenging condition that requires a nuanced and individualized approach. By integrating the latest diagnostic tools, therapeutic innovations, and patient-centered care strategies, clinicians can optimize outcomes and improve the quality of life for patients with AI. This article aims to provide a comprehensive review of the current state of knowledge and practice in the management of adrenal insufficiency, with a focus on addressing the unique needs of diverse patient populations and advancing the field through evidence-based recommendations.4,5

Diagnosis

The diagnosis of adrenal insufficiency (AI) represents a critical and multifaceted challenge in clinical endocrinology, requiring a high index of suspicion, a thorough understanding of the hypothalamic-pituitary-adrenal (HPA) axis, and the judicious use of biochemical and imaging modalities. Given the nonspecific and often insidious nature of its clinical presentation, AI is frequently underdiagnosed or misdiagnosed, leading to delayed treatment and increased morbidity. The diagnostic process involves a stepwise approach, beginning with clinical evaluation, followed by biochemical confirmation, and, when necessary, etiological investigation through imaging and additional specialized testing.5,6

Clinical Evaluation

The clinical presentation of AI is highly variable and depends on the underlying etiology, the severity of hormone deficiency, and the acuity of the condition. Patients with primary adrenal insufficiency (PAI), or Addison's disease, often exhibit symptoms related to both glucocorticoid and mineralocorticoid deficiency, including chronic fatigue, weight loss, anorexia, orthostatic hypotension, hyponatremia, hyperkalemia, and hyperpigmentation of the skin and mucous membranes due to elevated ACTH levels. In contrast, patients with secondary adrenal insufficiency (SAI) or tertiary adrenal insufficiency (TAI) typically present with symptoms of glucocorticoid deficiency alone, such as fatigue, weakness, and hypoglycemia, without hyperpigmentation or electrolyte abnormalities, as the renin-angiotensin-aldosterone system remains intact.5,6

A high index of suspicion is warranted in patients with a history of autoimmune diseases, pituitary or hypothalamic disorders, chronic glucocorticoid use, or recent adrenal hemorrhage or infection. Additionally, the presence of an adrenal crisis—a life-threatening emergency characterized by hypotension, hypoglycemia, and shock—should prompt immediate evaluation for AI.7

Biochemical Confirmation

The cornerstone of AI diagnosis lies in biochemical testing to assess the integrity of the HPA axis. The initial step involves measuring morning serum cortisol levels, which, if low (<3 µg/dL or 83 nmol/L), strongly suggest AI. However, intermediate cortisol levels (3–18 µg/dL or 83–500 nmol/L) require further dynamic testing to confirm the diagnosis.7

ACTH Stimulation Test (Cosyntropin Test):

The ACTH stimulation test is the most widely used diagnostic tool for AI. It involves the administration of synthetic ACTH (cosyntropin) and measurement of serum cortisol levels at baseline and 30 or 60 minutes post-injection. A peak cortisol level of <18 µg/dL (500 nmol/L) is indicative of AI. This test is highly sensitive for diagnosing PAI but may yield false-negative results in early or mild cases of SAI or TAI due to partial preservation of adrenal function.8

Insulin Tolerance Test (ITT):

The ITT is considered the gold standard for assessing the entire HPA axis. It involves inducing hypoglycemia through intravenous insulin administration and measuring cortisol and glucose levels at regular intervals. A peak cortisol level of <18 µg/dL (500 nmol/L) confirms AI. However, the ITT is contraindicated in patients with cardiovascular disease, epilepsy, or a history of severe hypoglycemia.8

Low-Dose ACTH Stimulation Test:

The low-dose ACTH stimulation test (1 µg of cosyntropin) is more sensitive than the standard-dose test for detecting partial or early HPA axis dysfunction, particularly in SAI or TAI.8

CRH Stimulation Test:

The CRH stimulation test is used to differentiate between SAI and TAI. It involves the administration of corticotropin-releasing hormone (CRH) and measurement of ACTH and cortisol levels. A blunted ACTH response suggests SAI, while a delayed or normal response points to TAI.8

Measurement of ACTH and Other Hormones

In patients with confirmed AI, measurement of plasma ACTH levels helps differentiate between PAI and SAI/TAI. Elevated ACTH levels (>2–3 times the upper limit of normal) indicate PAI, while low or inappropriately normal ACTH levels suggest SAI or TAI. Additionally, measurement of plasma renin activity and aldosterone levels is useful in PAI, as mineralocorticoid deficiency leads to elevated renin and low aldosterone levels.8

Etiological Investigation

Once AI is confirmed, identifying the underlying cause is essential for guiding long-term management.8

Primary Adrenal Insufficiency (PAI):

- **Autoimmune Adrenalitis:** The most common cause of PAI in developed countries, often associated with other autoimmune conditions (e.g., autoimmune polyglandular syndromes). Testing for adrenal autoantibodies (e.g., 21-hydroxylase antibodies) is recommended.8
- **Infections:** Tuberculosis and HIV-associated opportunistic infections should be considered, particularly in endemic regions.8
- **Genetic Disorders:** Congenital adrenal hyperplasia (CAH) and adrenoleukodystrophy (ALD) should be evaluated in pediatric patients or those with a family history of adrenal disease.8
- **Imaging:** Abdominal CT or MRI may reveal adrenal gland atrophy, calcifications, or enlargement.8

Secondary and Tertiary Adrenal Insufficiency (SAI/TAI):

- **Pituitary and Hypothalamic Imaging:** MRI of the pituitary gland is essential to identify structural abnormalities such as tumors, infarction, or infiltrative diseases.9
- **Assessment of Other Pituitary Hormones:** SAI is often associated with deficiencies in other pituitary hormones (e.g., TSH, GH, FSH/LH), necessitating a comprehensive pituitary function evaluation.9

Challenges in Diagnosis

The diagnosis of AI is complicated by several factors, including the overlap of symptoms with other common conditions (e.g., chronic fatigue syndrome, depression), the variability of cortisol levels due to stress or illness, and the limitations of available diagnostic tests. Furthermore, the interpretation of test results requires careful consideration of the patient's clinical context, medications (e.g., exogenous glucocorticoids, oral contraceptives), and comorbidities.9

The diagnosis of adrenal insufficiency demands a systematic and integrative approach, combining clinical acumen, biochemical testing, and advanced imaging techniques. Early and accurate diagnosis is paramount to prevent adrenal crises, optimize treatment, and improve patient outcomes. As our understanding of the HPA axis continues to evolve, future advancements in diagnostic biomarkers and imaging modalities hold promise for further refining the diagnostic process and enhancing the care of patients with AI.10

Treatment

The management of adrenal insufficiency (AI) is a complex and dynamic process that requires a meticulous, patient-centered approach to restore physiological hormone levels, prevent life-threatening complications, and optimize long-term outcomes. The cornerstone of treatment lies in glucocorticoid replacement therapy, with additional mineralocorticoid and androgen replacement as needed, depending on the type and severity of AI. Recent advancements in pharmacotherapy, coupled with a deeper understanding of the hypothalamic-pituitary-adrenal (HPA) axis, have revolutionized the management of AI, enabling more precise and individualized treatment regimens. However, challenges remain, particularly in special populations and in the prevention of adrenal crises. This section provides a comprehensive overview of the current therapeutic strategies for AI, emphasizing evidence-based practices, emerging therapies, and the importance of patient education and self-management.10

Glucocorticoid Replacement Therapy

Glucocorticoid replacement is the mainstay of treatment for all forms of AI, aiming to mimic the physiological circadian rhythm of cortisol secretion and prevent both under- and over-replacement.11

Hydrocortisone (Cortisol):

Hydrocortisone is the most commonly used glucocorticoid due to its short half-life and ability to closely replicate endogenous cortisol secretion. The typical daily dose ranges from 15–25 mg, divided into two or three doses, with the majority administered in the morning to align with the natural cortisol peak. However, conventional dosing regimens often fail to fully replicate the circadian rhythm, leading to suboptimal metabolic control and an increased risk of long-term complications, such as osteoporosis, cardiovascular disease, and impaired quality of life.11

Modified-Release Hydrocortisone Formulations:

Recent advancements in drug delivery systems have led to the development of modified-release hydrocortisone formulations, such as dual-release hydrocortisone (Plenadren) and chronocort. These formulations aim to better mimic the physiological cortisol profile by providing an immediate-release dose in the morning and a delayed-release dose in the afternoon or evening. Studies have demonstrated improved metabolic control, reduced weight gain, and enhanced quality of life with these formulations compared to conventional therapy.12

Prednisone and Dexamethasone:

Prednisone and dexamethasone are longer-acting glucocorticoids that may be used in select patients, particularly those with compliance issues or difficulty achieving adequate control with hydrocortisone. However, their prolonged duration of action increases the risk of over-replacement and associated complications, necessitating careful dose titration and monitoring.12

Circadian Rhythm-Based Therapies:

Emerging therapies, such as continuous subcutaneous hydrocortisone infusion (CSHI) pumps, represent a promising approach to replicating the physiological cortisol rhythm. These devices deliver hydrocortisone in a pulsatile manner, closely mimicking endogenous secretion patterns. Early studies have shown improvements in metabolic parameters, quality of life, and adrenal crisis prevention, although further research is needed to establish long-term efficacy and safety.12

Mineralocorticoid Replacement Therapy

Mineralocorticoid replacement is essential in patients with primary adrenal insufficiency (PAI), who exhibit aldosterone deficiency. Fludrocortisone, a synthetic mineralocorticoid, is the treatment of choice, typically administered at a dose of 0.05–0.2 mg once daily. Dose adjustment is guided by clinical parameters, including blood pressure, serum electrolytes, and plasma renin activity. Patients should be advised to maintain an adequate sodium intake and monitor for signs of fluid overload or hypertension.12

Adrenal Androgen Replacement Therapy

Dehydroepiandrosterone (DHEA) replacement may be considered in patients with PAI who experience symptoms of androgen deficiency, such as fatigue, depression, and reduced libido. While DHEA supplementation has been shown to improve quality of life and psychological well-being in some patients, its use remains controversial due to variable efficacy and potential side effects, including acne and hirsutism.13

Management of Adrenal Crises

Adrenal crises represent a medical emergency and require immediate intervention to prevent morbidity and mortality. Treatment involves the administration of high-dose intravenous hydrocortisone (100 mg bolus followed by 200 mg over 24 hours), fluid resuscitation with isotonic saline, and correction of hypoglycemia if present. Patients and caregivers should be educated on stress dosing of glucocorticoids during illness, surgery, or trauma to prevent crises.13

Special Populations

Pediatric Patients:

The management of AI in children requires careful dose adjustments to accommodate growth and development. Hydrocortisone is the preferred glucocorticoid due to its short half-life and ease of titration. Growth velocity, bone health, and pubertal development should be closely monitored.14

Pregnant Women:

Pregnancy necessitates close monitoring and dose adjustments to account for increased cortisol requirements, particularly during the second and third trimesters. Fludrocortisone doses may also need adjustment due to physiological changes in the renin-angiotensin-aldosterone system.15

Elderly Patients:

Elderly patients are at increased risk of glucocorticoid-induced complications, such as osteoporosis and cardiovascular disease. Lower doses of hydrocortisone and careful monitoring are recommended.15

Patient Education and Self-Management

Patient education is a critical component of AI management, empowering individuals to recognize symptoms of under- or over-replacement, adjust glucocorticoid doses during stress, and administer emergency hydrocortisone injections. Regular follow-up with an endocrinologist is essential to monitor treatment efficacy, adjust doses, and screen for complications.15

Emerging Therapies and Future Directions

Research into novel therapies, such as cortisol analogs with improved pharmacokinetic profiles and gene therapy targeting adrenal regeneration, holds promise for further advancing the management of AI. Additionally, the integration of digital health technologies, such as wearable devices and mobile applications, may enhance patient monitoring and adherence.16

The treatment of adrenal insufficiency has evolved significantly, with a shift towards more physiological and individualized approaches. By integrating the latest therapeutic advancements, patient education, and multidisciplinary care, clinicians can optimize outcomes and improve the quality of life for patients with AI. Ongoing research and innovation will continue to shape the future of AI management, addressing unmet needs and further refining treatment strategies.16

CONCLUSION

Adrenal insufficiency (AI) remains a complex and challenging endocrine disorder that demands a nuanced, patient-centered approach to optimize outcomes and improve quality of life. Over the past century, significant advancements in our understanding of the hypothalamic-pituitary-adrenal (HPA) axis, coupled with innovations in diagnostic and therapeutic modalities, have transformed the management of this condition. However, despite these strides, AI continues to pose substantial clinical challenges, particularly in the prevention of adrenal crises, the management of special populations, and the long-term sequelae of glucocorticoid replacement therapy.

The diagnosis of AI has been refined through the development of dynamic endocrine testing, such as the ACTH stimulation test and insulin tolerance test, as well as advanced imaging techniques that enable precise etiological characterization. These tools have facilitated earlier and more accurate diagnosis, reducing the risk of life-threatening complications and enabling timely intervention. Nevertheless, the nonspecific nature of AI symptoms and the limitations of current diagnostic tests underscore the need for continued research into novel biomarkers and diagnostic algorithms.

The treatment of AI has evolved from the rudimentary use of animal adrenal extracts to the development of sophisticated glucocorticoid replacement therapies that aim to replicate the physiological circadian rhythm of cortisol secretion. Conventional hydrocortisone regimens, while effective, often fall short of achieving optimal metabolic control, leading to an increased risk of long-term complications such as osteoporosis, cardiovascular disease, and impaired quality of life. The advent of modified-release hydrocortisone formulations and continuous subcutaneous hydrocortisone infusion pumps represents a significant leap forward, offering the potential for more physiological cortisol replacement and improved patient outcomes. Additionally, the role of mineralocorticoid and adrenal androgen replacement in primary AI has been well-established, addressing the multifaceted hormonal deficiencies inherent to this condition.

Despite these advancements, the management of AI is far from perfect. The risk of adrenal crises remains a persistent concern, necessitating robust patient education and self-management strategies to ensure timely stress dosing and

emergency interventions. Special populations, including pediatric patients, pregnant women, and the elderly, present unique challenges that require tailored approaches to balance hormone replacement with growth, development, and comorbid conditions. Furthermore, the long-term consequences of glucocorticoid therapy highlight the need for ongoing monitoring and dose optimization to minimize adverse effects.

Looking ahead, the future of AI management holds immense promise. Emerging therapies, such as cortisol analogs with improved pharmacokinetic profiles and gene therapy targeting adrenal regeneration, offer the potential for more precise and durable treatment options. The integration of digital health technologies, including wearable devices and mobile applications, may revolutionize patient monitoring and adherence, enabling real-time adjustments and personalized care. Additionally, continued research into the genetic and molecular underpinnings of AI may uncover novel therapeutic targets and biomarkers, further refining diagnostic and treatment strategies.

In conclusion, the management of adrenal insufficiency has made remarkable progress, yet significant challenges remain. By embracing a multidisciplinary approach that integrates the latest evidence-based practices, patient education, and emerging technologies, clinicians can optimize outcomes and enhance the quality of life for patients with AI. As our understanding of this complex disorder continues to evolve, so too will our ability to deliver personalized, effective, and compassionate care. The journey towards excellence in AI management is ongoing, and with continued innovation and collaboration, the future holds great promise for patients and providers alike.

REFERENCES

I. Hahner S, Ross RJ, Arlt W, Bancos I, Burger-Stritt S, Torpy DJ, et al. Adrenal insufficiency. Nat Rev Dis Primers. 2021;7:19. doi: 10.1038/s41572-021-00252-7.

II. Husebye ES, Pearce SH, Krone NP, Kampe O. Adrenal insufficiency. Lancet. 2021;397:613–29. doi: 10.1016/S0140-6736(21)00136-7.

III. Barthel A, Benker G, Berens K, Diederich S, Manfras B, Gruber M, et al. An update on Addison's disease. Exp Clin Endocrinol Diabetes. 2019;127:165–75. doi: 10.1055/a-0804-2715.

IV. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:364–89. doi: 10.1210/jc.2015-1710.

V. Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:3888–921. doi: 10.1210/jc.2016-2118.

VI. Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ. 2021;374:n1380. doi: 10.1136/bmj.n1380.

VII. Papierska L, Rabijewski M. Delay in diagnosis of adrenal insufficiency is a frequent cause of adrenal crisis. Int J Endocrinol. 2013;2013:482370. doi: 10.1155/2013/482370.

VIII. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341:1013–20. doi: 10.1056/NEJM199909303411401.

IX. Diederich S, Franzen NF, Bahr V, Oelkers W. Severe hyponatremia due to hypopituitarism with adrenal insufficiency: report on 28 cases. Eur J Endocrinol. 2003;148:609–17. doi: 10.1530/eje.0.1480609.

X. Garrahy A, Thompson CJ. Hyponatremia and glucocorticoid deficiency. Front Horm Res. 2019;52:80–92. doi: 10.1159/000493239.

XI. Benner BJ, Alsma J, Feelders RA. Hyponatraemia and hyperpigmentation in primary adrenal insufficiency. BMJ Case Rep. 2019;12:e227200. doi: 10.1136/bcr-2018-227200.

XII. Mohamed F, Raal FJ. Hyperpigmentation from Addison's disease. N Engl J Med. 2021;384:1752. doi: 10.1056/NEJMicm2018221.

XIII. Abdel-Malek ZA, Knittel J, Kadekaro AL, Swope VB, Starner R. The melanocortin 1 receptor and the UV response of human melanocytes: a shift in paradigm. Photochem Photobiol. 2008;84:501–8. doi: 10.1111/j.1751-1097.2008.00294.x.

XIV. Grossman AB. Clinical review: the diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab. 2010;95:4855–63. doi: 10.1210/jc.2010-0982.

XV. Kumar R, Carr P, Wassif W. Diagnostic performance of morning serum cortisol as an alternative to short synacthen test for the assessment of adrenal reserve; a retrospective study. Postgrad Med J. 2022;98:113–8. doi: 10.1136/postgradmedj-2020-138514.

XVI. Charoensri S, Chailurkit L, Muntham D, Bunnag P. Serum dehydroepiandrosterone sulfate in assessing the integrity of the hypothalamic-pituitary-adrenal axis. J Clin Transl Endocrinol. 2017;7:42–6. doi: 10.1016/j.jcte.2017.01.001.